NR1H3 and hepatocellular carcinoma: Therefore, we leveraged transcriptomic analyses performed on HCC cell‐lines treated with ligands activating NR1H3 (Huh7 cells treated with GW3965; Vazquez Salgado et al, 2022) or THRB (HepG2 cells treated with 3,3′,5‐triiodo‐L‐thyronine (T3) or GC‐1; Yuan et al, 2012).